FibroBiologics
FBLG
65 hedge funds and large institutions have $5.81M invested in FibroBiologics in 2025 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 23 increasing their positions, 13 reducing their positions, and 5 closing their positions.
77% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 13
40% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 5
3% more funds holding
Funds holding: 63 → 65 (+2)
0.03% more ownership
Funds ownership: 0.85% → 0.88% (+0.03%)
51% less capital invested
Capital invested by funds: $11.9M → $5.81M (-$6.04M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$727K |
| 2 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$71.4K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$68.9K |
| 4 |
AQR Capital Management
Greenwich,
Connecticut
|
+$46K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$31.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
-$122K |
| 2 |
OSAM
O'Shaughnessy Asset Management
Stamford,
Connecticut
|
-$80.8K |
| 3 |
Osaic Holdings
Scottsdale,
Arizona
|
-$41.9K |
| 4 |
CFP
Cascade Financial Partners
San Diego,
California
|
-$32.2K |
| 5 |
VF
Virtu Financial
New York
|
-$30K |
FBLG Hedge Fund Activity: Q1 2025 in Review
65 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in FibroBiologics (FBLG) for Q1 2025, worth a combined $5.81M — down 51% from $11.9M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new FBLG positions and 5 closed out — a net gain of 2 holders — while 23 added to existing stakes and 13 trimmed.
The largest buyer was Vanguard Group, adding an estimated $727K. The largest seller was Jane Street, exiting entirely with an estimated $122K sold.
- 65 institutional investors held FibroBiologics (FBLG) as of Q1 2025, up from 63 in Q4 2024.
- Funds reported $5.81M of FibroBiologics stock for Q1 2025, down 51% quarter-over-quarter.
- 7 funds opened new FibroBiologics positions in Q1 2025 and 5 closed out, a net change of +2 holders.
- The largest FibroBiologics buyer in Q1 2025 was Vanguard Group, an estimated $727K added.
- The largest FibroBiologics seller in Q1 2025 was Jane Street, an estimated $122K sold.
Based on aggregated 13F filings for Q1 2025.